A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.
The U.S. Food and Drug Administration approved Eli Lilly's drug, named Zepbound.
Zepbound is the latest diabetes drug approved for chronic weight management, joining Novo Nordisk's Wegovy, a high-dose version of its diabetes treatment Ozempic.
Those with diabetes, who have a harder time losing weight, cut about 12%, or nearly 27 pounds (12 kilograms), the FDA said.
Approved for weight loss in 2021, Wegovy helped people lose about 15% of their weight or 34 pounds (15 kilograms), according to study results.
Persons:
Eli Lilly's, dieters, Zepbound, Wegovy, Fatima Cody Stanford, tirzepatide, pare, ”, Katherine Saunders, Eli Lilly, Mounjaro, Kelly Burns, Burns
Organizations:
U.S . Food, Drug Administration, Novo Nordisk's Wegovy, FDA, Massachusetts General Hospital, New York's Weill Cornell Medicine, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP
Locations:
U.S, Zepbound, Wegovy, Massachusetts, Boston, St . Petersburg , Florida